U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06924424) titled 'Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma' on April 06.
Brief Summary: This study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma, Neoplasms
Intervention:
DRUG: Aponermin, pomalidomide, dexamethasone
Three drugs combination for R/R MM. Aponermin, 10mg/kg d1-5 Pomalidomide 4mg d1-21 Dexamethasone 20mg d1,d8,d15 Each treatment cycle is 28 days.
Recruitment Stat...